This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2008 Jun 12;453(7197):851-2.

doi: 10.1038/453851a.

Follow the leader

Kaori Tsuji¹, Kiichiro Tsutani

Affiliations

PMID: 18548049
DOI: 10.1038/453851a

Follow the leader

Kaori Tsuji et al. Nature. 2008.

. 2008 Jun 12;453(7197):851-2.

doi: 10.1038/453851a.

Authors

Kaori Tsuji¹, Kiichiro Tsutani

Affiliation

¹ Health Care Science Institute, Akasaka NOA 5F, 3-2-12 Akasaka, Minato-ku, Tokyo 107-0052, Japan.

PMID: 18548049
DOI: 10.1038/453851a

No abstract available

PubMed Disclaimer

Similar articles

Characteriation of clinical data packages using foreign data in new drug applications in Japan.
Tanaka M, Nagata T. Tanaka M, et al. Clin Pharmacol Ther. 2008 Sep;84(3):340-6. doi: 10.1038/sj.clpt.6100346. Epub 2007 Sep 5. Clin Pharmacol Ther. 2008. PMID: 17786162
StatBite: New drug approvals in Japan: a comparison of review times and number of employees.
[No authors listed] [No authors listed] J Natl Cancer Inst. 2010 Feb 3;102(3):150. doi: 10.1093/jnci/djq006. Epub 2010 Jan 27. J Natl Cancer Inst. 2010. PMID: 20107162 No abstract available.
Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
Tsuji K, Tsutani K. Tsuji K, et al. Eur J Pharm Biopharm. 2008 Mar;68(3):496-502. doi: 10.1016/j.ejpb.2007.07.013. Epub 2007 Aug 10. Eur J Pharm Biopharm. 2008. PMID: 17884403
[Review process of anticancer drugs in Japan].
Hori A. Hori A. Rinsho Ketsueki. 2006 Jul;47(7):626-32. Rinsho Ketsueki. 2006. PMID: 16910572 Review. Japanese. No abstract available.
[Drug development in Japan from the viewpoints of global pharmaceutical companies].
Seriu T. Seriu T. Rinsho Ketsueki. 2009 Jul;50(7):556-62. Rinsho Ketsueki. 2009. PMID: 19638723 Review. Japanese. No abstract available.

See all similar articles

Cited by

Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study.
Maeda H, Hara A, Ofuchi M, Shingai R, Misumi T, Murai Y. Maeda H, et al. Clin Transl Sci. 2023 Dec;16(12):2665-2674. doi: 10.1111/cts.13660. Epub 2023 Oct 17. Clin Transl Sci. 2023. PMID: 37815272 Free PMC article.
Oncology drug lag in Japan: has it improved over the last decade?
Tachibana Y, Narukawa M. Tachibana Y, et al. Int J Clin Oncol. 2023 Nov;28(11):1451-1460. doi: 10.1007/s10147-023-02395-x. Epub 2023 Aug 10. Int J Clin Oncol. 2023. PMID: 37561368
Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan.
Imamura CK, Takebe N, Nakamura S, Saya H, Ueno NT. Imamura CK, et al. Nat Rev Clin Oncol. 2010 Mar;7(3):127-8. doi: 10.1038/nrclinonc.2010.13. Nat Rev Clin Oncol. 2010. PMID: 20190792 No abstract available.
Assessing drug lag in new drug approvals by the Iran Food and Drug Administration compared to the U.S. FDA, EMA, and PMDA: A 20-year analysis (2001-2021).
Alipour S, Nadimi Parashkouhi S, Mojahedian M, Abbasian H. Alipour S, et al. Medicine (Baltimore). 2024 Jun 21;103(25):e38142. doi: 10.1097/MD.0000000000038142. Medicine (Baltimore). 2024. PMID: 38905367 Free PMC article.
Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials.
Shiga K, Shibata T, Miyata T. Shiga K, et al. Int J Clin Oncol. 2025 Jun;30(6):1109-1117. doi: 10.1007/s10147-025-02756-8. Epub 2025 Apr 11. Int J Clin Oncol. 2025. PMID: 40214879 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.